A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

BACKGROUND: Aflibercept is a novel decoy receptor that efficiently neutralizes circulating vascular endothelial growth factor (VEGF). A pediatric phase 1 trial was performed to define the dose limiting toxicities (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of aflibercept. METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bender, Julia Glade, Blaney, Susan M., Borinstein, Scott, Reid, Joel M., Baruchel, Sylvain, Ahern, Charlotte, Ingle, Ashish M., Yamashiro, Darrell J., Chen, Alice, Weigel, Brenda, Adamson, Peter C., Park, Julie R.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3445751/
https://ncbi.nlm.nih.gov/pubmed/22791883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0078
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars